• Home
• Prescribing Information
• Patient Product Information
• Important Safety Information
• Font Size
• Print Page

Sign Up For Updates

All fields marked with an asterisk (*) are required.

* Salutation:	Ms. Mrs. Mr. Dr.
* First name:
* Last name:
* I am a:	Please choose one Patient Family Member Caregiver or Friend Healthcare Professional Other
* This is my:	Home Address Work Address
* Address-Line 1:
Address-Line 2:
* City
* State	AK AL AR AZ CA CO CT DC DE FL GA HI IA ID IL IN KS KY LA MA MD ME MI MN MO MS MT NC ND NE NH NJ NM NV NY OH OK OR PA RI SC SD TN TX UT VA VT WA WI WV WY
* ZIP Code
* E-mail Address:
* Confirm E-mail Address:
* Preferred Method of Contact	Please choose one Phone eMail
I would like to receive e-mail updates including news on Hereditary Angioedema, Berinert, or other relevant information from CSL Behring.
I would like a CSL Behring representative to contact me by the preferred method indicated above.
Type in the verification word in the box below and click “Submit”:
Prior to submitting your information, please review our Privacy Policy.

Important Safety Information

Berinert®, C1 Esterase Inhibitor (Human) is for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE) in adult and adolescent patients. The safety and efficacy of Berinert for prophylactic therapy have not been established.

Immediately report to your physician or an emergency department any signs or symptoms of allergic or hypersensitivity reactions to Berinert, including hives, chest tightness, wheezing, turning blue, fast heartbeat, and shock. Also report any signs and symptoms of thrombosis, such as swelling and pain in the limbs or abdomen, chest pain, shortness of breath, loss of sensation or motor power, or altered consciousness or speech. If necessary, your doctor will immediately discontinue administration and initiate appropriate treatment.

Because Berinert is made from human blood, the risk that it may transmit infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In clinical studies, the most serious adverse reaction reported in subjects who received Berinert was an increase in the severity of pain associated with HAE. The most common adverse reactions, reported in over 4% of the subjects who received Berinert, were headache, abdominal pain, nausea, muscle spasms, pain, diarrhea, and vomiting.

Berinert has not been evaluated in pregnant women or nursing mothers; inform your doctor if you are pregnant or are planning to become pregnant, or if you are breastfeeding or plan to breastfeed. The safety and efficacy of Berinert have not been established in children (ages 0 through 12) or in the elderly.

Please see prescribing information for Berinert, with patient product information.

You are encouraged to report negative effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.